These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8276960)

  • 1. Pulsatile gonadotrophin releasing hormone stimulation after medium-term pituitary suppression in polycystic ovary syndrome.
    Scheele F; Hompes PG; van der Meer M; Schoute E; Schoemaker J
    Hum Reprod; 1993 Nov; 8 Suppl 2():197-9. PubMed ID: 8276960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone.
    Schachter M; Balen AH; Patel A; Jacobs HS
    Gynecol Endocrinol; 1996 Oct; 10(5):327-35. PubMed ID: 8915662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulsatile luteinising hormone releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome.
    Bayram N; van Wely M; Vandekerckhove P; Lilford R; van Der Veen F
    Cochrane Database Syst Rev; 2000; (2):CD000412. PubMed ID: 10796718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
    Cheung AP; Lu JK; Chang RJ
    Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome.
    Bayram N; van Wely M; van der Veen F
    Cochrane Database Syst Rev; 2004; 2003(1):CD000412. PubMed ID: 14973957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
    Filicori M; Flamigni C; Campaniello E; Meriggiola MC; Michelacci L; Valdiserri A; Ferrari P
    Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 2):1737-42. PubMed ID: 2122730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of ovulation with pulsatile subcutaneous administration of human menopausal gonadotropin in patients with polycystic ovary syndrome.
    Nakamura Y; Yamada H; Yoshida K; Manno T; Ubukata Y; Suzuki M; Yoshimura Y
    Horm Res; 1990; 33 Suppl 2():43-8. PubMed ID: 2128881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotrophin-releasing hormone antagonists for assisted conception.
    Al-Inany H; Aboulghar M
    Cochrane Database Syst Rev; 2001; (4):CD001750. PubMed ID: 11687120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
    Fulghesu AM; Lanzone A; Guida C; Nicoletti MC; Rossi P; Le Donne M; Caruso A; Mancuso S
    J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of polycystic ovarian disease by inducing ovulation with pulsatile subcutaneous administration of human menopausal gonadotrophin associated with luteinizing hormone-releasing hormone analogue.
    Nakamura Y; Yoshimura Y; Tamaoka Y; Ubukata Y; Yoshida K; Yamada H; Iizuka R; Suzuki M
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):395-402. PubMed ID: 3150824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
    Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
    J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of a gonadotrophin-releasing hormone agonist on treatment with low dose follicle stimulating hormone in polycystic ovary syndrome.
    Scheele F; Hompes PG; van der Meer M; Schoute E; Schoemaker J
    Hum Reprod; 1993 May; 8(5):699-704. PubMed ID: 8314962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study on follicle stimulation and ovulation induction in polycystic ovary syndrome (PCOS).
    Ito T; Michioka T; Kobayashi M; Narimatsu A; Yamashita S; Matsuzaki H; Kuramoto T; Numa F; Yakabe A
    Horm Res; 1990; 33 Suppl 2():32-4. PubMed ID: 2128879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does polycystic ovarian morphology influence the response to treatment with pulsatile GnRH in functional hypothalamic amenorrhea?
    Dumont A; Dewailly D; Plouvier P; Catteau-Jonard S; Robin G
    Reprod Biol Endocrinol; 2016 Apr; 14(1):24. PubMed ID: 27129705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist.
    Donderwinkel PF; Schoot DC; Pache TD; de Jong FH; Hop WC; Fauser BC
    Hum Reprod; 1993 Dec; 8(12):2027-32. PubMed ID: 8150898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.